New findings from the phase 3 TROPiCS-04 study have revealed that chemotherapy provides better outcomes for patients with pretreated advanced urothelial carcinoma (aUC) than sacituzumab govitecan (SG), as the study’s primary endpoint of improved overall survival (OS) was not met. In TROPiCS-04, a group of 711 patients who received prior platinum-based chemotherapy and checkpoint inhibitor therapy were randomized 1:1 to receive either SG 10 mg/kg intravenously (IV) on days 1 and 8 of 21- day cycles, or physician’s choice of chemotherapy (paclitaxel 175 mg/m2 IV, docetaxel 75 mg/m2 IV, or vinflunine 320 mg/m2 IV) on day ...
Advanced Urothelial Carcinoma
Advertisement
Latest News
PIVOT-10 expanded on PIVOT-02 by further investigating BEMPEG with nivolumab in cisplatin-ineligible patients.
At ESMO Congress 2024, Drs. Petros Grivas, Bernadett Szabados, and Karine Tawagi discuss ctDNA biomarkers.
Dr. Koshkin highlights phase 2 data on futibatinib plus pembrolizumab for advanced urothelial carcinoma.
Drs. Tawagi, Nizam encourage earlier monitoring and intervention to mitigate EV-induced neuropathy in certain patients.
Better quality of life and higher optimism showed to alter the perception people with metastatic disease have about cure.
Dr. Galsky discusses the value of HER2 status and the promising 75% ORR from the phase 2 trial.
Advertisement
Urothelial Carcinoma Knowledge Hubs
Curated clinical content based on urothelial cancer types, therapies, and technologies
Conference Coverage
Dr. Syan highlights advancements in pelvic medicine and reconstructive surgery, and progress in gender-specific challenges.
Dr. Syan shares her vision for the meeting and the lessons or feedback from the past two years that helped shape the program.
Dr. Sanchez-Salas comments on whether PSMA PET is useful for determining optimal candidates for focal therapy.
Dr. Sanchez-Salas details strategies for selecting between focal therapy versus active surveillance or definitive treatments.
Dr. Kaouk presented on the benefits of surgery for managing biochemically recurrent prostate cancer post-radiation.
Dr. Kaouk explains how a multidisciplinary team should be integrated into the management of RCC.
Advertisement
Section Editor
Amanda Nizam, MDGenitourinary Medical Oncologist | Cleveland Clinic
Advertisement
Get the latest UC research straight to your inbox.
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.